+918042781554
Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.
Upto 40% of patients undergoing coronary angioplasty and stenting have high bleeding risk (HBR) characteristics. Guidelines recommend 3-6 months of dual antiplatelet therapy (DAPT) for HBR patients undergoing percutaneous coronary intervention (PCI). Resolute Onyx is a thin sturted conformable stent with biocompatible polymer and sustained drug release for several months. The Onyx ONE randomised control trial (RCT) demonstrated non inferior outcomes of Resolute Onyx compared to a polymer free drug coated stent in a broad range of patients receiving one month of DAPT. In conjunction with Onyx ONE RCT, Onyx ONE Clear, which is a prospective multicenter, single arm study supports the use of one month of DAPT in HBR patients.